deltatrials
Completed NA INTERVENTIONAL 2-arm NCT00549874

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

Sponsor: GlaxoSmithKline

Conditions Type 2 Diabetes
Interventions Glyburide Rosiglitazone
Updated 6 times since 2017 Last updated: Nov 8, 2007 Started: Feb 28, 2002 Completion: Nov 30, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed NA

  2. Sep 2024 — Present [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  5. Jun 2018 — Jan 2021 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • University of Michigan
Data source: University of Michigan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations